Axsome Therapeutics (NASDAQ:AXSM) announced Wednesday a settlement agreement with U.K.-based Hikma Pharmaceuticals ...

In a report released today, Joseph Thome from TD Cowen maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report), with a price ...

Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report) has earned a consensus rating of “Buy” from the fifteen ratings ...

Axsome Therapeutics (AXSM) announced that it has entered into a settlement agreement with Hikma Pharmaceuticals (HKMPF), resolving patent ...

Supplemental New Drug Application (sNDA) submission anticipated in 3Q 2025NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Axsome ...

Biopharmaceutical firm Axsome Therapeutics (NASDAQ:AXSM) reported mixed fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 18. The company achieved substantial revenue growth, with sales ...

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its price objective hoisted by stock analysts at Robert W. Baird from ...

Axsome's stock has risen 47% since my August recommendation, driven by FDA approvals and revenue growth. See why I maintain ...

Axsome Therapeutics gained more than $1 billion in market value Monday, after the brain drug developer disclosed a patent settlement with Teva Pharmaceuticals that will keep a generic copy of Axsome’s ...

Axsome Therapeutics reports strong Q4 2024 revenues, driven by increased sales of Auvelity and Sunosi. Anticipated milestones and FDA approval for Symbravo make AXSM a top pick for 2025.

Axsome is advancing an industry-leading neuroscience pipeline of multiple, innovative, late-stage, patent-protected product candidates addressing a broad range of serious psychiatric and ...

Axsome Therapeutics, a biopharmaceutical company targeting central nervous system (CNS) disorders, develops novel therapies for depression, narcolepsy, and other CNS conditions. Its current ...